The molecular changes manifested by a cancer cell provide the opportunity for personalised treatment which is exemplified by the use of inhibitors like trastuzumab and lapatinib to treat cancer patients with amplifications of the RTK ERBB2 [6, 7]. Here, ERBB2 is linked to cancer.